PBZ
LOE ApproachingNDAORALELIXIR
Approved
Feb 1948
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PBZ is an oral elixir small-molecule drug approved in 1948 by Novartis, making it a legacy product with over 75 years of clinical use. The mechanism of action and specific indications are not documented in current records, suggesting it may be a historic or discontinued formulation. It represents a classic small-molecule therapeutic from the mid-20th century pharmaceutical era.
LOE Approaching
With LOE approaching and minimal commercial data available, this product likely has a small or legacy team focused on managed decline and supply continuity rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
With zero linked job openings and approaching LOE, PBZ offers minimal career advancement or visibility for ambitious pharma professionals. Roles available are maintenance-focused, centered on regulatory compliance, supply continuity, and managing decline rather than growth or innovation.
Brand Manager (Legacy/Maintenance)Regulatory Affairs Specialist
Worked on PBZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.